表紙
市場調査レポート

がん検出・管理向け分子バイオマーカー

Molecular Biomarkers for Cancer Detection and Management

発行 Insight Pharma Reports 商品コード 274870
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
がん検出・管理向け分子バイオマーカー Molecular Biomarkers for Cancer Detection and Management
出版日: 2013年07月01日 ページ情報: 英文 105 Pages
概要

当レポートでは、がん検出・管理向け分子バイオマーカーという極めて動的な診断分野における近年の進歩および新たな方向性に焦点を当て、がんバイオマーカーの背景と歴史、商業化、およびマーケティング動向について調査しており、基礎研究のセグメント別(疾病検出・予後・コンパニオン診断)調査、主要企業42社のプロファイル、前述のセグメントにおける商業活動と市場力学の展望、および専門家へのインタビューなどを提供しています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 歴史・背景

  • 第1世代のがんバイオマーカー
  • がんバイオマーカーの分類
  • オミックス時代のがんバイオマーカー
  • 失敗した取り組み・障害

第3章 基礎研究

  • スクリーニング・検出・リスク・モニタリング
  • 予後・予測
  • コンパニオン診断
  • 転移
  • マイクロRNA (miRNA)

第4章 商業アプリケーション

  • スクリーニング・検出・リスク評価・モニタリングバイオマーカー
  • 予後・予測バイオマーカー
  • コンパニオン診断バイオマーカー
  • 創設者 Luis Diaz, MD へのインタビュー

第5章 市場力学

  • 競合環境
  • 売上推計・予測
  • M&A
  • がん検出・リスク・予後アッセイ契約
  • コンパニオン診断アッセイ契約
  • 調査結果

第6章 所見・結論

  • コンパニオン診断
  • 循環腫瘍細胞・核酸
  • EMTバイオマーカー
  • 腫瘍異質性
  • コスト・医療費償還

第7章 インタビュー記録

目次

New to Insight Pharma Reports is Molecular Biomarkers for Cancer Detection and Management: Technologies, Markets, and Trends. This report focuses on recent progress and new directions in this highly dynamic diagnostic field. Covering extensive background and history, commercialization, and marketing trends of cancer biomarker technologies, this report provides heavy detail of historical and evolutionary aspects of cancer biomarkers, delineating some of the difficulties researchers face in validating and commercializing their candidate assays.

Significant highlights of the report include:

  • Basic research conducted in both academic and commercial settings divided into three segments: disease detection, prognosis, and companion diagnostics.
  • 42 detailed descriptions of companies (including GenomeDx Biosciences, Genomic Health, Life Technologies, Foundation Medicine, Roche Molecular Systems, and many more!).
  • Commercial activity in the three foregoing sectors, and the perspective of market dynamics.
  • Focuses on trends and conclusions.
  • Data depicted across 15 tables and figures.

Following company descriptions and commercial applications are transcribed interviews of five individuals who are highly knowledgeable in the field, including:

  • Genome Diagnostics
  • Billings Clinic
  • Scientia Advisors
  • Cynvenio Biosystems
  • Johns Hopkins University School of Medicine

Also provided in the report are survey results of 107 individuals who actively work in the cancer biomarker space. Results are depicted across 9 tables.

Table of Contents

Executive Summary

  • Background and history
  • Basic research
  • Commercial applications
  • Market dynamics
  • Survey results
  • Trends and conclusions

CHAPTER 1: Introduction

  • Scope and contents

CHAPTER 2: Background and History

  • First-generation cancer biomarkers
  • Categorization of cancer biomarkers
    • Disease detection biomarkers
    • Prognostic biomarkers
    • Companion diagnostic biomarkers
  • Omic era cancer biomarkers
  • Failed efforts and stumbling blocks

CHAPTER 3: Basic Research

  • Screening, detection, risk, and monitoring
    • Screening
  • Prognosis and prediction
  • Companion Diagnostics
  • Metastasis
    • Circulating tumor cells
    • Exosomes
  • MicroRNA (miRNA)

CHAPTER 4: Commercial Applications

  • Screening, detection, risk assessment, and monitoring biomarkers
    • Alere
    • Allegro Diagnostics
    • Atossa Genetics
    • Biophysical Corporation
    • Exact Sciences
    • Exosome Diagnostics
    • Matrix-Bio
    • MDx Health
    • Mitomics
    • Myriad Genetics
    • Oncimmune
    • Onconome
    • Predictive Biosciences
    • Sphingotec
  • Prognosis and prediction biomarkers
    • Agendia
    • Abbott Molecular
    • Atossa Genetics
    • Biocept
    • bioTheranostics
    • DiagnoCure
    • GenomeDx Biosciences
    • Genomic Health
    • Gen-Probe
    • Life Technologies
    • MetaStat
    • Predictive Biosciences
    • Skyline Diagnostics
    • Trovagene
    • Veridex
  • Companion diagnostic biomarkers
    • 20/20 GeneSystems
    • Abbott Molecular
    • Cynvenio
    • Dako (Agilent)
    • Epic Sciences
    • Foundation Medicine
    • Genomic Health
    • Molecular Response Corp.
    • Nodality
    • Personal Genome Diagnostics
  • Interview with founder, Luis Diaz, MD
    • Qiagen
    • Roche Molecular Systems

CHAPTER 5: Market Dynamics

  • Competitive Environment
  • Sales Estimates and Projections
  • Mergers and acquisitions
  • Cancer detection, risk, and prognostic assay deals
    • Liquid Biopsy AB and Roche
    • Oxford Gene Technology
    • Abbott and Stanford University
    • Ipsogen and Personal Genome Diagnostics (PDGx)
  • Companion diagnostic assay deals
    • Abbott and Merck
    • Affymetrix and Massachusetts General Hospital (MGH)
    • Agilent/Dako and Genentech
    • Eli Lilly
    • Foundation Medicine
    • GE Healthcare and Insight Genetics
    • Genomic Health and OncoMed Pharmaceuticals
    • HTG Molecular Diagnostics and Merck
    • Life Technologies and Others
    • Qiagen and Boehringer Ingelheim
    • Quintiles and Oxford Cancer Biomarkers
    • Roche/Ventana and other companies
    • Verastem and Labcorp
  • Survey Results

CHAPTER 6: Observations and Conclusions

  • Companion diagnostics
  • Circulating tumor cells and nucleic acids
  • EMT biomarkers
  • Tumor Heterogeneity
  • Costs and reimbursement

CHAPTER 7: Interview Transcripts

  • Luis Diaz, MD, Associate Professor of Oncology, Johns Hopkins School of Medicine; Chief Medical Officer and Founder Personal Genome Diagnostics
  • Jorge Nieva, MD, Oncologist and Hematologist,Billings Clinic,Billings Montana
  • Harry Glorikian, Managing Partner and Founder, Scientia Advisors
  • Paul Dempsey, Ph.D., Chief Science Officer, CynvenioBiosystems
  • Scott Kern, M.D., Professor of Oncology and Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • About Cambridge Healthtech Institute
Back to Top